

Title	c9, t11, c15-CLNA and c9, t11, t15-CLNA from Lactobacillus plantarum ZS2058 ameliorate DSS-induced colitis in mice
Authors	Ren, Qing;Yang, Bo;Zhang, Hao;Ross, R. Paul;Stanton, Catherine;Chen, Haiqin;Chen, Wei
Publication date	2020-03-03
Original Citation	Ren, Q., Yang, B., Zhang, H., Ross, R. P., Stanton, C., Chen, H. and Chen, W. (2020) 'c9, t11, c15-CLNA and c9, t11, t15-CLNA from Lactobacillus plantarum ZS2058 Ameliorate DSS-Induced Colitis in Mice', Journal of Agricultural and Food Chemistry, In Press, doi: 10.1021/acs.jafc.0c00573
Type of publication	Article (peer-reviewed)
Link to publisher's version	https://pubs.acs.org/doi/10.1021/acs.jafc.0c00573 - 10.1021/acs.jafc.0c00573
Rights	© 2020 American Chemical Society. This document is the Accepted Manuscript version of a Published Work to appear in final form in Journal of Agricultural and Food Chemistry, copyright © American Chemical Society after peer review and technical editing by the publisher. To access the final edited and published work see https://pubs.acs.org/doi/10.1021/acs.jafc.0c00573
Download date	2023-05-05 01:42:06
Item downloaded from	http://hdl.handle.net/10468/9746



UCC

University College Cork, Ireland
 Coláiste na hOllscoile Corcaigh

Bioactive Constituents, Metabolites, and Functions

c9, t11, c15-CLNA and c9, t11, t15-CLNA from *Lactobacillus plantarum* ZS2058 Ameliorate DSS-Induced Colitis in Mice

Qing REN, Bo Yang, Hao Zhang, R. Paul Ross, Catherine Stanton, Haiqin Chen, and Wei Chen

J. Agric. Food Chem., **Just Accepted Manuscript** • DOI: 10.1021/acs.jafc.0c00573 • Publication Date (Web): 03 Mar 2020

Downloaded from pubs.acs.org on March 9, 2020

Just Accepted

"Just Accepted" manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides "Just Accepted" as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. "Just Accepted" manuscripts appear in full in PDF format accompanied by an HTML abstract. "Just Accepted" manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). "Just Accepted" is an optional service offered to authors. Therefore, the "Just Accepted" Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the "Just Accepted" Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these "Just Accepted" manuscripts.

**c9, t11, c15-CLNA and c9, t11, t15-CLNA from *Lactobacillus plantarum* ZS2058
Ameliorate DSS-Induced Colitis in Mice**

Qing Ren^{†,‡}, Bo Yang^{†,‡}, Hao Zhang^{†,‡,§,¶}, R. Paul Ross^{ζ, ξ}, Catherine Stanton^{ζ, θ, ξ},
Haiqin Chen^{*†,‡}, Wei Chen^{†,‡,§,||}

[†] State Key Laboratory of Food Science and Technology, Jiangnan University, Wuxi,
Jiangsu 214122, P. R China

[‡] School of Food Science and Technology, Jiangnan University, Wuxi, Jiangsu 214122,
P. R China

[§] National Engineering Research Center for Functional Food, Jiangnan University,
Wuxi, Jiangsu 214122, P. R China

[¶] Wuxi Translational Medicine Research Center and Jiangsu Translational Medicine
Research Institute Wuxi Branch, Wuxi, Jiangsu 214122, P. R China

^ζ International Joint Research Center for Probiotics & Gut Health, Jiangnan University,
Wuxi, China

^ξ APC Microbiome Ireland, University College Cork, Cork, Ireland

^θ Teagasc Food Research Centre, Moorepark, Fermoy, Cork, Ireland

^{||} Beijing Innovation Centre of Food Nutrition and Human Health, Beijing Technology
and Business University (BTBU), Beijing 100048, P.R. China

*** Corresponding author:** Haiqin Chen

State Key Laboratory of Food Science and Technology, Jiangnan University, Wuxi,
Jiangsu 214122, P. R China

E-mail: haiqinchen@jiangnan.edu.cn

Telephone: 0086-510-85197239

ORCID: Haiqin Chen: 0000-0002-6850-3160

ABSTRACT: To investigate the specific functions of conjugated fatty acids (CFAs) produced by the probiotic bacterium, α -linolenic acid was isomerized by *Lactobacillus plantarum* ZS2058, and two different conjugated α -linolenic acid (CLNA) isomers were successfully isolated: c9, t11, c15-CLNA (CLNA1) and c9, t11, t15-CLNA (CLNA2). The effects and mechanism of CLNA crude extract and individual isomers on colitis were explored. CLNA significantly inhibited weight loss, the disease activity index, colon shortening. Additionally, CLNA alleviated histological damage, protected colonic mucous layer integrity and significantly upregulated the concentration of tight junction proteins (ZO-1, occludin, E-cadherin1 and claudin-3). CLNA significantly attenuated the level of proinflammatory cytokines (TNF- α , IL-1 β , and IL-6) while upregulating the expression of the colonic anti-inflammatory cytokine IL-10 and nuclear receptor PPAR γ . Moreover, CLNA increased the activity of oxidative stress-related enzymes (SOD, GSH and CAT) and the myeloperoxidase activity was significantly decreased by CLNA. Meanwhile, the concentrations of CLNA in the liver and conjugated linoleic acid (CLA) in colonic content were significantly increased because of the treatment of CLNA. Furthermore, CLNA could rebalance the intestinal microbial composition of colitis mice, including increasing the α -diversity. CLNA1 and CLNA2 increased the abundance of *Ruminococcus* and *Prevotella*, respectively.

KEYWORDS: Conjugated linolenic acid (CLNA), Colitis, Intestinal barrier function, Oxidative stress, Gut microbiota

■ INTRODUCTION

Conjugated fatty acids (CFAs), which are defined as the positional and geometric isomers of unsaturated fatty acids, contain one or more nonmethylene interrupted double bonds in either cis or trans conformation.¹ One CFA that has been intensively investigated is conjugated linoleic acid (CLA), which exhibits a variety of health benefits, including anticancer,²⁻³ antioxidation,⁴ antiatherosclerotic,⁵ antidiabetic,^{6,7} and antiobesity effects.⁸⁻⁹ In addition to CLA, the conjugated linolenic acid (CLNA) isomers, which are another type of CFA, have recently received enhance attention due to their biological benefits being similar to those of CLA. CLNAs can be collected from plant oil or bacterial fermentation broth, and plant-derived CLNAs have been extensively studied, while bacteria-derived CLNAs not yet been studied. The typical plant-derived CLNAs contain c9, t11, c13-CLNA, c9, t11, t13-CLNA, t9, t11, c13-CLNA, c8, t10, c12-CLNA and t8, t10, c12-CLNA, while typical bacteria-derived CLNAs contain c9, t11, c15-CLNA and t9, t11, c15-CLNA. Although the cis-trans properties of the double bonds are different, they all have conjugated double bonds. Some conjugated double bonds with particular cis-trans properties, such as c9, t11, in fatty acids can enhance their functionality. In this paper, the isomers of c9, t11, c15-CLNA and t9, t11, c15-CLNA were first separated from the fermentation of *L. plantarum* ZS2058, and their function in a mice model was investigated.

IBD comprises two types of inflammatory conditions, crohn's disease (CD) and ulcerative colitis (UC). Although the mechanism of IBD has not been fully figured out, several factors are considered in IBD, including immunologic abnormalities, intestinal

69 barrier dysfunction, oxidative stress, and expansion of inflammatory mediators.¹⁰⁻¹¹
70 Some treatments alleviate IBD by inhibiting inflammation, such as aminosalicylates
71 and corticosteroids, particularly hydrocortisone, budesonide, prednisone and
72 antibiotics.¹²⁻¹³ However, there may be some side effects when using anti-inflammatory
73 drugs, such as headache, abdominal pain, diarrhea and nasopharyngitis.¹⁴⁻¹⁶ Currently,
74 there are some new therapies for IBD which are different from traditional medicine,
75 such as prebiotics and some microbial metabolites like unsaturated fatty acids.

76 The effects of plant-derived conjugated linolenic acid on colitis have been widely
77 studied. Tarek Boussetta et al. proved that punicic acid (c9, t11, c13-CLNA) can inhibit
78 TNF- α -induced priming of NADPH oxidase, which is related to the
79 p38MAPKinase/Ser345-p47phox-axis and MPO release.¹⁷ C9, t11, t13-CLNA can
80 improve DSS-induced colitis in mice by improving the level of peroxisome-activated
81 receptor- γ (PPAR γ).¹⁸ The structures of c9, t11, c15-CLNA (CLNA1) and t9, t11, c15-
82 CLNA (CLNA2) were exactly similar to plant-derived CLNA; therefore, they may have
83 similar effects on colitis. To date, there was only in vitro experiments on *Lactobacillus*-
84 derived CLNA, which have proved that it can inhibit the growth of SW480 cells and is
85 more toxic than LNA and CLA.¹⁹⁻²⁰ No study has reported the efficacy of the two
86 isomers in vivo, perhaps due to the difficulty of screening high-yield CLNA strains and
87 the complexity of extracting and separating CLNA isomers. Therefore, one of the
88 purposes of this study is to explore the function of CLNA1 and CLNA2 in colitis and
89 provide a medical basis for the use of conjugated fatty acids as adjuvants in the
90 treatment of colitis. In addition, different isomers usually showed different bioactivity

due to cis, trans configurations of their double bonds.²¹ For example, all-trans conjugated fatty acids have more effective tumor suppressing activity.²² Therefore, the other purpose of this study was to explore the difference between the two isomers in colitis.

■ MATERIAL AND METHODS

Microorganism Cultivation and Preparation of the CLNA Mixture. *L. plantarum* ZS2058 was subcultured twice in de Man, Rogosa and Sharpe (mMRS) medium at 37°C for 24 h, inoculated into 2 L of mMRS with α -linolenic acid (Nu-check Prep, Elysian, MN) at a final concentration of 30 mg/ml, and cultured for 48 h. After culturing, the fermentation broth was placed in a pear-shaped separatory funnel with the ratio of fermentation broth:isopropanol:n-hexane = 3:2:3 (v/v/v), shaken thoroughly, and allowed to stand for 15 min. The solution was layered, and the upper transparent n-hexane layer was collected. The n-hexane layer was then evaporated on a rotary evaporator and redissolved in methanol (chromatography grade) to a concentration of 40 mg/mL.

Separation of CLNA and Purity Detection. The crude extracts were separated by RP-HPLC on an Ultimate[®] 5 μ m C30 semipreparative column (10×250 mm) (Yuxu Technology, Shanghai, China) by a Waters 2545 RP-HPLC. The CLNA isomers were separated in methanol:water:formic acid (80:20:0.01, vol/vol) at a flow rate of 5 mL/min with an injection volume of 700 μ L. The CLNA fragments were detected by a UV detector at absorbances of 205 nm and 233 nm, and fractions containing the single isomer were collected automatically when both absorbances were detected. The

methanol and water from the pooled fractions were removed by rotary evaporation (37°C), and then the single CLNA isomer was re-extracted with methanol for storage. The purities of the extracted CLNA1 (c9, t11, c15-CLNA) and CLNA2 (t9, t11, c15-CLNA) were determined by GC-MS as previously described.²³

Animals and Diets. Seven-week-old male C57 BL6/J mice were housed in the Animal Housing Unit of Jiangnan University for one week to adapt. The mice were maintained at a room temperature of 23-25°C, room humidity of 40-70% and a 12-h light/dark cycle. The mice were kept in standard laboratory IVC cages, where sterile water and standard laboratory chow were provided libitum.

The fatty acids were dissolved in skim milk and oral gavaged, and the composition of fatty acids of every group were listed in Table 1. All the animals were fed with standard laboratory chow; its component was listed in Table 2. The detailed experimental protocols were as follows: 72 C57BL6/J male mice were randomly divided into 9 groups: control (no DSS), DSS + vehicle, DSS + α -linolenic acid (ALA), DSS + punicic acid (PA), DSS + CLNA mixture, vehicle + CLNA mixture (no DSS), DSS + CLNA1, DSS + CLNA2, DSS + drug (mesalazine, 5-aminosalicylic acid). Fatty acids, drugs or vehicle was given once a day by gavage from days 1 to 14. All the fatty acids were emulsified in 10% skim milk, and the dose of every type of CLNA isomer was 400 μ g/d. 400 μ g/d was the dose of pure isomer to ensure the effective contrast. The CLNA mixture and PA (Jian HaiRui Co., Ltd, Jian, China) was quantified by the purity. 5-aminosalicylic acid (Etiasa Pharmaceutical Co., Ltd., Saint-Cloud, Paris, France) was dissolved in PBS, 5 mg/d. DSS (MP Biomedicals, LLC, Irvine, CA) was

dissolved in the water and was given from days 7 to 14. The animal experiment protocol has been approved by the Ethics Committee of Jiangnan University, China (JN. No.20181130c0900515[258]) and in compliance with the Directive of 2010/63/European Community.

Induction and Assessment of Colitis. The dextran sodium sulfate was dissolved in drinking water for mice at a concentration of 3% to induce the colitis.²⁴ Mice were allowed to drink freely and DSS water was replaced daily. During DSS treatment from days 7 to 14, the stool consistency, weight loss, and hematochezia were detected daily to determine the disease activity index (DAI)²⁵⁻²⁶. The occult blood in the feces was measured by an Occult Blood kit (Nanjing Jiancheng Co., Ltd., Nanjing, China). The standard for evaluation of the disease activity index were listed in the Table 3. And the mice were sacrificed at the day 15. The Carnoy's solution (ethanol:chloroform:acetic acid, 6:3:1, vol/vol/vol) was used to fix the colon segments at 4°C for 8 h. Then the colon tissue was embedded in paraffin, sectioned (5 mm) and stained with alcian blue or H&E staining. Panoramic MIDI Digital Slide Scanner (3D Histech Co., Ltd., Budapest, Hungary) was used to scan and capture the images of the dyed sections. The severity of colonic histological damage in each mice was graded and the valuation system of pathological scores was based on a previously reported method.²⁷

Biochemical Assays. The frozen colons stored at -80°C were weighed and homogenized in saline solution by a high flux tissue crushing instrument. Then the homogenate was centrifuged at 12,000 g, 4°C for 10 min. The activity of myeloperoxidase (MPO) in colon was detected by commercially available kits (Nanjing

Jiancheng Co., Ltd., Jiangsu, China) according to the manufacturer's instructions. The activity of antioxidant enzymes (SOD, GSH, CAT) were assessed by enzyme-linked immunosorbent assay (ELISA) kits (Nanjing SenBeiJia Biotechnology Co., Ltd., Jiangsu, China). The total protein concentration in tissue homogenate was measured by the BCA protein assay kit (Beyotime Biotechnology, Shanghai, China). In the result of MPO and antioxidant enzymes, the activity were presented in the form of U/g colon protein and U/mg colon protein respectively.

Level of Cytokines in Colon Tissues. The frozen colons stored at -80°C were weighed and homogenized in potassium phosphate containing 1% phosphatase inhibitor and 1% protease inhibitors (Beyotime Biotechnology, Shanghai, China). Then, the cytokines IL-10, IL-1 β , IL-6, and TNF- α were detected by the R&D ELISA Kit (R&D Systems, Minneapolis, MN) according to the instructions. The total protein concentration in tissue homogenate was measured by the BCA protein assay kit (Beyotime Biotechnology, Shanghai, China), and the results were presented in the form of pg/mg total colon protein.

Tight Junction Protein Bioassays. The concentrations of E-cadherin 1, occludin, ZO-1, and claudin-3 in colon tissue homogenate were measured by commercially available ELISA kits (Nanjing SenBeiJia Biotechnology Co., Ltd., Nanjing, Jiangsu, China). The results were presented in the form of pg/ml colon homogenization buffer.

Fatty Acid Analysis. The liver and colonic content were weighed and homogenized in potassium phosphate, then the fatty acids were extracted and methylated as previously described. Then fatty acid methyl ester were dissolved in hexane and detected by gas

chromatography (GC)–mass spectrometry (the parameters of the instrument were as previously described).^{28,29}

Mouse Fecal Genome Extraction and Analysis. A certain amount of mouse feces was weighed, and the genome was extracted with a Fast DNA Spin Kit for Feces (MP Biomedicals, LLC, Irvine, CA). After extraction, the V3–V4 region of the 16S ribosomal RNA (rRNA) gene was PCR-amplified using the primers 341F: 5'-CCTAYGGGRBGCASCAG-3' and 806R: 5'-GGACTACNNGGGTATCTAAT-3', nucleic acid electrophoresis was carried out using the PCR products, and the corresponding strip was purified by the QIA quick Gel Extraction Kit (Qiagen, Germany). Both the genome extraction kit and the DNA purification kit were performed according to the manufacturers' instructions. After sequencing, bioinformatics analysis of the 16S rRNA sequence data was carried out as previously described.³⁰

Statistical Analysis. All data are presented as the mean \pm SEM of each group (n=8). The statistical significance between DSS group and other groups were analyzed by SPSS 19.0 software (SPSS Inc., Chicago, IL) in the arithmetic ANOVA. A p value of <0.05 indicates a significant difference. Data analysis was performed and mapped by GraphPad Prism 7 (GraphPad software, Inc.) Microbiota-related analyses were conducted by QIIME and R 3.5.0. Linear discriminant analysis (LDA) effect size (LEfSe) was performed by Python 2.7 and R 3.5.0.

■ RESULTS

Preparation and Detection of c9, t11, c15-CLNA and c9, t11, t15-CLNA. The α -linolenic acid was isomerized by *L. plantarum* ZS2058, which can transform

approximately 60% of ALA into CLNA³¹, then the CLNA mixtures were extracted from the fermentation. Fatty acids with conjugated double bonds are characterized by an absorption peak at 233 nm. Fragment ion peak signals for these two isomers are m/z 292 and 261. A total of 600 mg of c9, t11, c15-CLNA (CLNA1) and c9, t11, t15-CLNA (CLNA2) was collected by preparative liquid chromatography. The purities of CLNA1 and CLNA2 were 93.09% and 94.09%, respectively, and the chemical structures of the two isomers are shown in Figure 1C. The cis-trans property of the C₁₅ double bond of CLNA1 and CLNA2 was different. The double bond positions in plant-derived CLNAs were universally located at C₉, C₁₁, C₁₃, while the *Lactobacillus*-derived CLNA in the current study was located at C₉, C₁₁, C₁₅.

CLNA1 and CLNA2 Alleviate DSS-induced Colitis in Mice. The changes in the body weight and disease activity index (DAI) were measured daily during DSS treatment, and the colon length was measured after the mice were euthanized. Four days after DSS administration, the weight of the mice began to drop dramatically, and the final weight was 8.3% lower than the initial weight. Feeding the mice with CLNA mixture, CLNA1 and CLNA2 showed 5.7%, 6.0% and 7.0% weight loss, respectively (**Figure 2A**), demonstrating that the weight loss of the other groups was relieved compared with that of the DSS group. With the treatment of DSS, the body weight loss and DAI of mice increasing daily (**Figure 2B**).

The DAI indicates the severity of colitis during modeling in mice. The DSS group presented the highest DAI, which manifested the most serious weight loss, diarrhea and gross bleeding. The DAI was considerably reduced in the other six groups, but ALA

showed a relatively weaker effect. At the end of the experiment on day 14, the DAI for the DSS group reached a mean of 9.38, while oral administration of CLNAs, PA and drug markedly decreased the DAI to approximately 5.25.

Colon length characterizes the degree of inflammation in colon tissue and is an important indicator in colitis models. DSS challenge led to colon length shortening by 22.9% compared to that of the control group, whereas puniceic acids and CLNA2 resulted in colon shortening by 12.1% and 16.8% compared to the control group. This indicated that CLNA appeared to significantly recover the colon length. Pretreatment with CLNA1 (5.31 ± 0.181) and CLNA mixture (5.18 ± 0.120) appeared to partially recover the colon length, but not significantly (**Figure 2C**).

H&E staining was used to observe histopathological injury (**Figure 2D**). In normal mice, the colon mucosa is intact, the villi are neat, and the crypt structure is healthy. The goblet cells were abundant in the colon tissue of normal mice, and no inflammatory cell infiltration or mucosal erosion can be observed. However, in the mice with colitis, increased loss of submucosal structures, epithelial crypts and irregular crypts as well as more widespread bowel edema can be observed. These characteristics in DSS colon tissue mean that the colitis model was successfully established. The histological injury score (**Figure 2E**) was evaluated based on the H&E staining images, and the score showed quantifiable results of tissue damage. The score of the mice in DSS group (9.67 ± 0.25) was significantly higher than normal mice (0.00 ± 0.00) ($P < 0.0001$). Treatments with CLNA1, CLNA mixture and PA significantly reduced the inflammation score of the colon. This indicated that CLNA either from *Lactobacillus*

or plants can relieve inflammatory cellular infiltration, submucosal edema, loss and hyperplasia of crypts, and severe epithelial structure damage. From the results of histopathological score, CLNA1 showed the most effective protection on the injury of colon tissue. Tissue damage was reduced by treatment with ALA, which indicated weaker effects compared to CLNA1 and CLNA mixture. And the drug also showed a significant remission of colon tissue, which showed that the positive control group made sense.

CLNA1 and CLNA2 Regulate Inflammatory Cytokine Level in Colonic Tissue. To evaluate the effects of CLNA on inflammatory cytokines, the level of proinflammatory cytokines and anti-inflammatory cytokines in colonic tissue was analyzed. Treatment with DSS significantly increased the level of the cytokines IL-1 β (**Figure 3A**), TNF- α (**Figure 3B**) and IL-6 (**Figure 3D**), whereas oral administration of CLNAs markedly inhibited the DSS-induced upregulation of cytokine concentrations. Notably, TNF- α , the most significant proinflammatory cytokine, decreased by 1.45-fold by CLNA1, 1.82-fold by CLNA2 and 1.92-fold by drug in the colon compared to the DSS group. DSS significantly reduced the expression of IL-10 (**Figure 3C**), whereas this change was attenuated by CLNAs. PPAR- γ (**Figure 3E**) showed no significant change between the control, CLNA control, DSS and drug groups. However, the other five groups treated with various C18:3 fatty acids all showed an increase in the expression of PPAR- γ , which indicated that this change was characteristic of fatty acids. In particular, the effects of CLNA1 (77.53 ± 3.82) and CLNA mixture (70.247 ± 5.52) on PPAR- γ were more obvious compared to the DSS group (56.99 ± 1.28).

CLNA1 and CLNA2 Protect the Colonic Mucous Layer and Epithelium Structure.

To investigate the effects of CLNAs on the mucous layer and goblet cells, the protein of mucin2 (MUC2) was measured (**Figure 4B**). The concentration of MUC2 showed a significant reduce in the DSS-treated mice (278.04 ± 6.31), whereas CLNA1 (339.28 ± 6.47), CLNA2 (343.78 ± 5.92) and ALA (330.13 ± 6.03) treatments maintained its content at normal levels compared with levels in the control group (334.90 ± 11.78). Other groups also indicated a tendency of protection on the mucous layer compared to the DSS group, although there was no significant difference. In the DSS group, the colon tissue slice stained by alixin blue (**Figure 4A**) showed that the mucin produced by goblet cells were severely damaged. CLNA1, CLNA2 and CLNA mixture significantly protected against the destruction of the mucosal layer, which were stronger than ALA at the same dose.

To evaluate the effects of CLNAs on the epithelium structure, the expression of tight junction proteins, including ZO-1 (**Figure 4C**), occludin (**Figure 4D**), E-cadherin1 (**Figure 4E**), claudin-3 (**Figure 4F**), and in the colon was measured. Treatment with mesalazine, CLNA1, CLNA2, CLNA mixture and ALA significantly increased the concentrations of the four key TJ proteins compared with the DSS group. Moreover, the protective effects of CLNAs on E-cadherin 1 and claudin-3 were stronger than mesalazine. From the overall results of the four TJ proteins, the PA displayed a weaker protective effect on the intestinal barrier compared with CLNAs, which indicated that the CLNAs derived from *Lactobacillus* may be better than those from plants. There was no obvious difference between the CLNA1, CLNA2, and CLNA

mixture groups, so it is impossible to conclude which isomer is more potent.

CLNA1 and CLNA2 Regulated Oxidative Stress. Oxidative stress is the essential cause of cell and tissue damage. It can result in abnormal metabolism of oxygen free radicals and excessive activation of apoptosis. Oxygen free radicals could result in the release of inflammatory mediators.³² And many papers have reported that plant-derived CLNA showed an antioxidant activity.³³ To investigate the influence of *Lactobacillus* derived CLNAs on oxidative stress, CAT activity (**Figure 5A**), SOD activity (**Figure 5B**) and GSH-PX (**Figure 5C**) activity in the colon were measured. All these enzymes play key roles in protecting cells from damage induced by inflammation and oxidative stress. There was no significant change between the control, DSS and CLNA control groups. However, increased levels of the three indexes were observed in the other treatment groups. Treatment with CLNA1 significantly increased SOD and GSH activity 1.29- and 1.48-fold compared with DSS treatment, respectively. In addition, CLNA2 could significantly increase the level of CAT 1.27-fold compared with DSS. The activity of SOD and GSH-PX in colon tissues were significantly increased by CLNA1, while CLNA2 significantly increased CAT activity, which indicated that CLNA alleviated colitis by inhibiting oxidative stress. In addition, CLNA1 showed a more remarkable influence on oxidative stress. These results were similar to those of studies on plant-derived CLNA. PA and α -ESA have been proven to reduce oxidative stress and lipid peroxidation and restore antioxidant enzymes such as superoxide dismutase, catalase, and glutathione peroxidase.³⁴ Treatment with ALA or PA could induce a higher activity of CAT and SOD. For the drug control group, CAT activity

showed an obvious improvement compared to other groups. To evaluate the effects of CLNA on colonic inflammatory enzymes, the activity of MPO in colon, which can reflect neutrophil infiltration, was measured. All the treatments in this experiment can significantly decrease the activity of MPO induced by DSS. Only ALA group showed a relatively weak effect on MPO compared with other treatment groups (**Figure 5D**).

The Fatty Acid Composition in the Blood, Liver and Colonic Contents. To evaluate the distribution of orally administered CLNA in mice, the composition of fatty acids in blood, liver and colonic contents was analyzed. The composition of fatty acids in blood showed no significant difference among the nine groups (**Figure 6A**). No CLNA or CLA was detected in the blood, which may be due to the content being too low to detect or the conjugated fatty acids being metabolized at the point of blood collection. There was a considerable change in liver and colonic contents, which mainly focused on the proportion of CLA or CLNA in total fatty acids. In the liver, the percentages of CLNA in total fatty acids from the CLNA control and CLNA mixture groups were 3.04 ± 0.17 and 1.48 ± 0.23 , respectively, which manifested an increase compared to the control (2.39 ± 0.38) and DSS groups (0.70 ± 0.12) (**Figure 6B**). Other five groups showed no significant differences on the content of CLNA in liver compare to DSS group. Interestingly, unlike the liver, there was no significant difference in the ratio of CLNA in colonic contents between the nine groups. However, the ratio of CLA in total fatty acids increased significantly in the CLNA treatment group. The CLNA Mix group (1.74 ± 0.22) showed the most obvious enhancement in the CLA ratio, which was 3.28-fold compared with that of the DSS group (0.55 ± 0.11). In addition, the CLNA control

group also showed an increase in the CLA percentage at 0.77 ± 0.06 compared with the control group at 0.09 ± 0.09 . These results indicated that CLNA was eventually metabolized into CLA in the contents of the colon. (**Figure 6C**). Another interesting result indicated that the DSS group showed a higher CLA content than the control group, while the content of CLA in the CLNA mixture group was also higher than that in the CLNA control group. This may be because DSS-induced colitis can result in the production of CLA. In addition, ALA can also significantly increase the composition of CLA. Whereas PA group was similar to drug group without significant increase on the content of CLA.

CLNA1 and CLNA2 Influenced the Intestinal Microbiota. To determine the correlation between gut microbiota and the effects of CLNA treatment, the gut microbiota of mice treated with CLNAs, DSS, PA, ALA, and mesalazine and the control group were studied based on 16S rDNA amplicon sequencing. The microbial distribution of nine groups on the phylum level was analyzed (**Figure 7A**). Compared with the control group, the intestinal microbial structure of mice in the DSS group changed significantly. The predominant phyla in control group were Bacteroidetes (68.19%), Firmicutes (20.09%) and Verrucomicrobia (6.36%) (**Figure 7A**). However, DSS treatment dramatically altered the bacterial composition at the phylum level, and the relative abundance of Proteobacteria increased from 0.92% to 16.33%, while the relative abundances of Bacteroidetes and Verrucomicrobia decreased to 53.64% and 4.67%, respectively (**Figure 7A**). The proportion of Firmicutes showed no significant change. However, CLNA1 significantly increased the abundance of Firmicutes. And

355 there was a great improvement on the abundance of *Deferribacteres* in drug group
356 (5.18%) compared to that in DSS group (1.27%).

357 α -Diversity was evaluated by the Chao1 and Shannon indexes (**Figure 7B**). Chao1
358 reflects the community richness of species within a single sample, while the Shannon
359 index represents microbial diversity. The Chao1 and Shannon indexes in the DSS group
360 were much lower than those in the control group, and they were significantly increased
361 by drug treatment. In addition, the Chao1 of the CLNA1, CLNA mixture and ALA
362 groups was also significantly different from that of the DSS group.

363 The gut microbiota diversity among different groups was analyzed by the LDA
364 effect size (LEfSe) (**Figure 7C, 7D**). The LDA score histogram was drawn to identify
365 statistically significant biomarkers and reveal the dominant microorganisms in each
366 group. The proportion of major bacterial communities largely shifted within the
367 different treatment groups. Among them, *Turicibacter* was dominant in the DSS group;
368 Firmicutes was dominant in the CLNA control group; *Parabacteroides* and
369 Porphyromonadaceae were the dominant microbes in the CLNA mixture group; and
370 Clostridiales and Clostridia were dominant microbes in the CLNA1 group. *Bacteroides*
371 and Bacteroidaceae were the dominant microbes in the ALA group. Prevotellaceae and
372 *Provetella* were dominant microbes in the CLNA2 group. DSS significantly decreased
373 Bacteroidetes and increased Proteobacteria. However, there was no dominant
374 microorganisms in drug control, which meant the abundance of microorganisms in drug
375 control showed no significant superiority compared with other groups. Furthermore,
376 the correlations between the colonic CLA concentration, TJ proteins, differential

microorganisms, and inflammation markers were analyzed. Colon length, histological scores, MPO, and DAI were the characteristic index in colitis and had higher weightings in the network analysis (**Figure 7E**). The concentration of colonic CLA positively correlated with *Desulfovibrio* and *Enterobacter* but negatively correlated with *Coprococcus*.

■ DISCUSSION

Probiotics have been claimed to possess functions such as suppressing inflammation, protecting the intestinal barrier, and increasing the body's antioxidant capacity.³⁵⁻³⁶ The benefits of probiotics have been attributed to certain beneficial metabolites produced by them. In this study, we used *Lactobacillus plantarum* ZS2058 to isomerize α -linolenic acid and assess the function of the CLNA produced. The structure of *Lactobacillus*-derived CLNA is different from that of plant-derived CLNA, and they can be defined as a new material synthesized by bacteria. Until now, CLNA1 and CLNA2 have not been comprehensively studied, and there have been no functional *in vivo* studies on any *Lactobacillus*-derived single isomer of CLNA.

There was no abnormality in the control mice fed the CLNA mixture; therefore, it was speculated that the CLNA mixture was safe for 14 days of gavage. Tom et al. added 30.33% CLNA (c9, t11, c15-CLNA + c9, t13, c15-CLNA) to the diet of neonatal pigs and concluded that short-term intake of CLNA was safe.³⁷ In addition, the weight of the mice after 14 days of gavage of the CLNA mixture was less than that of the control mice, indicating that *Lactobacillus*-derived CLNA can lower body weight and weight gain. This is similar to the effect of plant-derived CLNA, such as punicic acid or α -

399 ESA, on obese mice.³⁸⁻⁴⁰ From the results of the composition of conjugated fatty acids
400 in the blood, liver and colonic contents, there was no obvious change in the blood.
401 Hiroyuki reported that the inhibition of colonic tumors by pomegranate seed oil (70%
402 c9, t11, c13-CLNA) was associated with an increased content of c9, t11-CLA in the
403 lipid fraction of the colonic mucosa and liver.⁴¹ CLA has been thoroughly certified to
404 alleviate colon cancer or colitis, so the function of CLNA may partially be due to the
405 increase in CLA in mice. In our study, the CLNA significantly increased in the liver,
406 while the CLA significantly increased in the colonic contents of mice given CLNA. We
407 hypothesized that CLNAs may be converted to CLA in the gut of mice.

408 PPARs are receptors for endogenous lipid molecules representing promising new
409 targets for the treatment and prevention of IBD.⁴² PPAR γ can inhibit the activation and
410 nuclear import of NF- κ B by the I κ B- α pathway in which NF- κ B plays a key role in the
411 regulation of the inflammatory response and pathogenesis of IBD.⁴³ PPAR-gamma is
412 also an important target during the conjugated linolenic acids work on some diseases
413 like IBD and obesity.⁴² The expression of PPAR- γ in mice treated with CLNA1 and
414 CLNA mixture was significantly increased compared with the control group. This was
415 consistent with the plant-derived CLNA and CLA. The loss of functional PPAR γ or
416 PPAR δ impaired the anti-inflammatory effects of punicic acid, such as upregulated
417 Foxp3 expression in T-cells and suppressed TNF- α .⁴⁴ α -ESA was also identified as a
418 natural PPAR γ agonist and found to be effective in ameliorating disease-associated
419 phenotypes in mice with DSS colitis.⁴⁵ Bassaganya Riera et al. used PPAR γ knockout
420 mice to prove that CLA was able to reduce colitis by activating PPAR γ .⁴⁶ CLA induced

apoptosis in HT-29 and Caco-2 cells by upregulating PPAR γ .⁴⁷ CLA in the colon targeted myeloid cell PPAR γ to suppress colitis.⁴⁸ Overall, the CLNA1 and CLNA mixture alleviated colitis by targeting PPAR γ to reduce inflammation, while CLNA2 showed an ambiguous effect on PPAR γ .

A physical barrier was formed by the epithelium and the mucosal layer to avoid the potentially toxic and noxious agents to disseminate into the underlying tissue, which induced the inflammation in the colon. The alteration in cytokine profiles, in turn, further trigger the decline in tight junctions. Therefore, a vicious cycle of mucosal barrier dysfunction and inflammation is established.⁴⁹⁻⁵⁰ Treatments with *Lactobacillus*-derived CLNAs increased the concentration of MUC2, contributing to the integrity of the colonic mucous layer and goblet cells. Tight junction proteins connect enterocytes and play an important role in the integrity of the intestinal barrier.⁵¹ The CLNA1, CLNA2 and CLNA mixture significantly upregulated TJ proteins (E-cadherin 1, ZO-1, claudin-3, and occludin) and CLNA1 showed a stronger role in protecting the intestinal barrier than PA. *Lactobacillus*-derived CLNA also manifested stronger regulation of the expression of relative cytokines than PA. As for the level of cytokine, PA just showed significance on IL-6, but *Lactobacillus* derived CLNA showed significance on IL- β , TNF- α and PPAR-gamma. So *Lactobacillus*-derived CLNA showed more effective influence against colitis based on the TJ protein and cytokine results. However, no obvious difference was observed in the expression of TJ proteins and cytokines between the CLNA1 and CLNA2 groups.

Interaction disorder between intestinal microbes has been confirmed as a critical

defect resulting in intestinal inflammation.⁵² In the current study, DSS decreased bacterial species richness and shifted the bacterial community composition. The CLNA1 isomer significantly increased the α -diversity, and the CLNA control group was more diverse than the control group. A higher abundance of the phylum Verrucomicrobia was observed in the CLNA2 and ALA groups, which was more than twice as abundant as the DSS group. Verrucomicrobia was considered to be associated with the higher expression of MUC2.⁵³ In humans, there is an overall trend toward lower biodiversity and decreased abundance of Firmicutes in people with IBD compared with controls.⁵⁴ CLNA1 increased the abundance of the phylum Firmicutes approximately 1.5 times compared with the DSS group. At the genus level, CLNA1 treatment significantly increased the abundance of *Parabacteroides* and *Dorea*. CLNA2 increased the abundance of *Prevotella*, which had a positive association with the control group.⁵⁵ Ce'line et al. reported that PUFA-derived bacterial metabolites, including CLNA and CLA, were positively correlated with specific fecal bacteria (*Bifidobacterium spp.*, *Eubacterium ventriosum* and *Lactobacillus spp.*).⁵⁶ The abundance of *Bifidobacterium* was exactly improved in the CLNA control group. *Bacteroides fragilis* strains can invade intestinal tissues and cause damage.⁵⁷ DSS significantly increased the abundance of *Bacteroides* compared to the control and CLNA control groups; however, no significant decrease was observed in the other treatment groups. Thus, our results indicated that CLNA treatment partially prevented the microbiota changes induced by DSS.

In the current study, c9, t11, c15-CLNA and c9, t11, t15-CLNA were proven to

alleviate colitis in mice and have different functions compared with other fatty acids. From the weight loss, colon length, DAI and pathological scores, CLNA1, CLNA mix and PA showed relatively stronger effects on colitis, while CLNA2 and ALA showed relatively weak effects. For cytokines, mucin protein, tight junction proteins and antioxidant enzymes, CLNA1 and CLNA mixture showed a strong regulation on those indexes, while CLNA2, PA and ALA showed a relatively weak regulation. The primary mechanisms of relieving DSS-induced colitis by the two isomers involved inhibiting proinflammatory factors, protecting mucosal barriers, and regulating oxidative stress and intestinal microbial damage. CLNA entered the bowel lumen and then increased the concentration of CLA, which could relieve colitis through all of the above aspects.³⁰ Furthermore, CLNA in the bowel lumen improved the activity of antioxidant-related enzymes, which could improve the intestinal barrier. At the same time, CLNA could directly enter into the mucus layer and epithelial cells to regulate MUC2 and TJ proteins. In addition, CLNA can enter the lamina propria of mice and regulate the levels of pro-inflammatory or anti-inflammatory cytokines to reduce the inflammatory response. CLNA could increase the α -diversity in colonic contents and regulate the bacterial flora. These results will assist us explore the mechanism of CLNAs to reduce colitis and investigate the mechanism of CLNA regulating other immune-related diseases, so as to guide the further development of CLNA research.

■ ACKNOWLEDGEMENT

This research was supported by the National Natural Science Foundation of China (No. 31722041, 31801521, 31530056), the Fundamental Research Funds for the Central

487 Universities (No. JUSRP51702A, JUSRP11733) , the national first-class discipline
488 program of Food Science and Technology (JUFSTR20180102), and the Jiangsu
489 Province “Collaborative Innovation Center for Food Safety and Quality Control”, the
490 Postgraduate Research & Practice Innovation Program of Jiangsu Province
491 (KYCX18_1763)

492 ■ **AUTHOR INFORMATION**

493 **Corresponding Author**

494 (Haiqin Chen) E-mail: haiqinchen@jiangnan.edu.cn

495 **Telephone:** 0510-85197239

496 **ORCID**

497 Haiqin Chen: 0000-0002-6850-3160

498 ■ REFERENCE

- 499 1. Hennessy, A. A.; Ross, P. R.; Fitzgerald, G. F.; Stanton, C., Sources and Bioactive Properties of
500 Conjugated Dietary Fatty Acids. *Lipids* **2016**, *51* (4), 377-97.
- 501 2. Shinohara, N.; Tsuduki, T.; Ito, J.; Honma, T.; Kijima, R.; Sugawara, S.; Arai, T.; Yamasaki, M.;
502 Ikezaki, A.; Yokoyama, M.; Nishiyama, K.; Nakagawa, K.; Miyazawa, T.; Ikeda, I., Jacaric acid, a
503 linolenic acid isomer with a conjugated triene system, has a strong antitumor effect in vitro and in vivo.
504 *Biochim Biophys Acta* **2012**, *1821* (7), 980-8.
- 505 3. Gasmi, J.; Thomas Sanderson, J., Jacaric acid and its octadecatrienoic acid geoisomers induce
506 apoptosis selectively in cancerous human prostate cells: a mechanistic and 3-D structure-activity study.
507 *Phytomedicine* **2013**, *20* (8-9), 734-42.
- 508 4. Paul, D.; Dey, T. K.; Mukherjee, S.; Ghosh, M.; Dhar, P., Comparative prophylactic effects of
509 alpha-eleostearic acid rich nano and conventional emulsions in induced diabetic rats. *J Food Sci Technol*
510 **2014**, *51* (9), 1724-36.
- 511 5. Kotwal, S.; Min, J.; Sullivan, D.; Perkovic, V.; Neal, B., Omega 3 Fatty Acids and Cardiovascular
512 Outcomes Systematic Review and Meta-Analysis. *Circ Cardiovasc Qual Outcomes* **2012**, *5* (6), 808-
513 818.
- 514 6. Vanessa, R.; Jolene, M. M.; Clare, R.; Garry, R.; Martin, R.; Gary, D.; Karen, R.; Graham, H.;
515 Sinead, T.; Moloney, A. P., Inter-organ proteomic analysis reveals insights into the molecular
516 mechanisms underlying the anti-diabetic effects of cis-9, trans-11-conjugated linoleic acid in ob/ob mice.
517 *Proteomics* **2010**, *12* (3), 461.
- 518 7. Castro-Webb, N.; Ruiz-Narvaez, E. A.; Campos, H., Cross-sectional study of conjugated linoleic
519 acid in adipose tissue and risk of diabetes. *Am J Clin Nutr* **2012**, *96* (1), 175-181.
- 520 8. Sengupta, A.; Gupta, S. S.; Nandi, I.; Ghosh, M., Conjugated linolenic acid nanoparticles inhibit
521 hypercholesterolemia induced by feeding a high-fat diet in male albino rats. *J Food Sci Technol* **2015**,
522 *52* (1), 458-464.
- 523 9. Koba K; Imamura J; Akashoshi A; Kohno-Murase J; Nishizono S; Iwabuchi M; Tanaka K; M, S.,
524 Genetically Modified Rapeseed Oil Containing cis-9,trans-11,cis-13-Octadecatrienoic Acid Affects
525 Body Fat Mass and Lipid Metabolism in Mice. *J Agri Food Chem* **2007**, *55* (9), 3741.
- 526 10. Goyal, N.; Rana, A.; Ahlawat, A.; Bijjem, K. R.; Kumar, P., Animal models of inflammatory bowel
527 disease: a review. *Inflammopharmacology* **2014**, *22* (4), 219-33.
- 528 11. Liu, Y.; Wang, X.; Hou, Y.; Yin, Y.; Qiu, Y.; Wu, G.; Hu, C.-A. A., Roles of amino acids in
529 preventing and treating intestinal diseases: recent studies with pig models. *Amino Acids* **2017**.
- 530 12. Green, J. R. B.; Lobo, A. J.; Holdsworth, C. D.; Leicester, R. J.; Gibson, J. A.; Kerry, G. D.;
531 Hodgson, H. J. F.; Parkins, K. J.; Taylor, M. D., Balsalazide is more effective and better tolerated than
532 mesalamine in the treatment of acute ulcerative colitis. *Gastroenterology* **1998**, *114* (1), 15-22.
- 533 13. Tanja Birrenbach, Ulrich Böcker. Inflammatory bowel disease and smoking. A review of
534 epidemiology, pathophysiology, and therapeutic implications. *Inflam Bowel Dis* **2004**, *10*(6):848-859.
- 535 14. Lichtenstein, G. R.; Gordon, G. L.; Zakko, S.; Murthy, U.; Sedghi, S.; Pruitt, R.; Merchant, K.;
536 Shaw, A.; Bortey, E.; Forbes, W. P., Clinical trial: once-daily mesalamine granules for maintenance of
537 remission of ulcerative colitis – a 6-month placebo-controlled trial. *Aliment Pharm & Ther* **2010**, *32* (8),
538 990-999.
- 539 15. Yongjun; Wang; Claire; Parker; Brian; Feagan; John, Oral 5-aminosalicylic acid for maintenance
540 of remission in ulcerative colitis 2016.

- 541 16. Zenlea, T.; Peppercorn, M. A., Immunosuppressive therapies for inflammatory bowel disease.
542 *World J Gastroentero* **2014**, *20* (12), 3146-3152.
- 543 17. Boussetta, T.; Raad, H.; Letteron, P.; Gougerot-Pocidalo, M. A.; Marie, J. C.; Driss, F.; El-Benna,
544 J., Punicic acid a conjugated linolenic acid inhibits TNF α -induced neutrophil hyperactivation and
545 protects from experimental colon inflammation in rats. *PLoS One* **2009**, *4* (7), e6458.
- 546 18. Lewis, S. N.; Lera, B.; Guri, A. J.; Pinyi, L.; Raquel, H.; Josep, B. R.; Bevan, D. R., %J Plos One,
547 Dietary α -eleostearic acid ameliorates experimental inflammatory bowel disease in mice by activating
548 peroxisome proliferator-activated receptor- γ . *Plos One* **2011**, *6* (8), e24031.
- 549 19. Coakley, M.; Banni, S.; Johnson, M. C.; Mills, S.; Devery, R.; Fitzgerald, G.; Paul Ross, R.; Stanton,
550 C. J. L., Inhibitory Effect of Conjugated α -Linolenic Acid from Bifidobacteria of Intestinal Origin on
551 SW480 Cancer Cells. *Lipids* **2009**, *44* (3), 249-256.
- 552 20. Hennessy, A. A.; Ross, P.; Devery, R.; Stanton, C., Bifidobacterially produced, C18:3 and C18:4
553 conjugated fatty acids exhibit in vitro anti-carcinogenic and anti-microbial activity. *Eur J Lipid Sci Tech*
554 **2016**, *118* (11), 1743-1758.
- 555 21. Fontes, A. L.; Pimentel, L. L.; Simoes, C. D.; Gomes, A. M. P.; Rodriguez-Alcala, L. M., Evidences
556 and perspectives in the utilization of CLNA isomers as bioactive compounds in foods. *Crit Rev Food Sci*
557 *Nutr* **2017**, *57* (12), 2611-2622.
- 558 22. Yasui, Y.; Hosokawa, M.; Kohno, H.; Tanaka, T.; Miyashita, K., Growth inhibition and apoptosis
559 induction by all-trans-conjugated linolenic acids on human colon cancer cells. *Anticancer Research* **2006**,
560 *26* (3A), 1855-1860.
- 561 23. Yang, B.; Chen, H.; Stanton, C.; Chen, Y. Q.; Zhang, H.; Chen, W., Mining *bifidobacteria* from the
562 neonatal gastrointestinal tract for conjugated linolenic acid production. *Bioengineered* **2017**, *8* (3), 232-
563 238.
- 564 24. Wirtz, S.; Neufert, C.; Weigmann, B.; Neurath, M. F., Chemically induced mouse models of
565 intestinal inflammation. *Nature Protocols* **2007**, *2* (3), 541-546.
- 566 25. Murthy, S. N.; Cooper, H. S.; Shim, H.; Shah, R. S.; Ibrahim, S. A.; Sedergran, D. J., Treatment of
567 dextran sulfate sodium-induced murine colitis by intracolonic cyclosporin. *Dig Dis Sci* **1993**, *38* (9),
568 1722-1734.
- 569 26. Mennigen, R.; Nolte, K.; Rijcken, E.; Utech, M.; Loeffler, B.; Senninger, N.; Bruewer, M., Probiotic
570 mixture VSL#3 protects the epithelial barrier by maintaining tight junction protein expression and
571 preventing apoptosis in a murine model of colitis. *Am J Physiol Gastr L* **2009**, *296* (5), G1140-9.
- 572 27. Dieleman, L.; Palmen, M. J. H. J.; Akol, H.; Bloemena, E.; Rees, E. P. V., Chronic experimental
573 colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines. *Clin Exp*
574 *Immunol* **1999**, *114* (3), 385-391.
- 575 28. Yang, B.; Chen, H.; Gao, H.; Wang, J.; Stanton, C.; Ross, R. P.; Zhang, H.; Chen, W.,
576 Bifidobacterium breve CCFM683 could ameliorate DSS-induced colitis in mice primarily via conjugated
577 linoleic acid production and gut microbiota modulation. *J Funct Foods* **2018**, *49*, 61-72.
- 578 29. Yang, Q.; Wang, S.; Ji, Y.; Chen, H.; Zhang, H.; Chen, W.; Gu, Z.; Chen, Y. Q., Dietary intake of
579 n-3 PUFAs modifies the absorption, distribution and bioavailability of fatty acids in the mouse
580 gastrointestinal tract. *Lipids Health Dis* **2017**, *16* (1), 10.
- 581 30. Chen, Y.; Yang, B.; Ross, R. P.; Jin, Y.; Stanton, C.; Zhao, J.; Zhang, H.; Chen, W., Orally
582 Administered CLA Ameliorates DSS-Induced Colitis in Mice via Intestinal Barrier Improvement,
583 Oxidative Stress Reduction, and Inflammatory Cytokine and Gut Microbiota Modulation. *J Agric Food*
584 *Chem* **2019**.

31. Yang, B.; Chen, H.; Gao, H.; Ren, Q.; Zhang, H.; Chen, W. J. J. o. A. M., Genetic determinates for conjugated linolenic acid production in *Lactobacillus plantarum* ZS2058 *J Appl Microbiol* **2020**.
32. Lei; Shi; Yi; Dai; Boyi; Jia; Yafei; Han; Guo; Tianhong, The inhibitory effects of Qingchang Wenzhong granule on the interactive network of inflammation, oxidative stress, and apoptosis in rats with dextran sulfate sodium-induced colitis *J Cell Biochem* **2018**.
33. Yuan, G. F.; Chen, X. E.; Li, D., Conjugated linolenic acids and their bioactivities: a review. *Food Funct* **2014**, 5 (7), 1360-8.
34. Saha, S. S.; Ghosh, M., Antioxidant and anti-inflammatory effect of conjugated linolenic acid isomers against streptozotocin-induced diabetes. *Br J Nutr* **2012**, 108 (6), 974-83.
35. Zhai, Q.; Tian, F.; Zhao, J.; Zhang, H.; Narbad, A.; Chen, W., Oral Administration of Probiotics Inhibits Absorption of the Heavy Metal Cadmium by Protecting the Intestinal Barrier. *Appl Environ Microbiol* **2016**, 82 (14), 4429-4440.
36. Majid, M.; Nasir, B.; Zahra, S. S.; Khan, M. R.; Mirza, B.; Haq, I. U., Ipomoea batatas L. Lam. ameliorates acute and chronic inflammations by suppressing inflammatory mediators, a comprehensive exploration using in vitro and in vivo models. *Bmc Complementary & Alternative Medicine* **2018**, 18 (1), 216.
37. Castellano, C. A.; Plourde, M.; Briand, S. I.; Angers, P.; Giguere, A.; Matte, J. J., Safety of dietary conjugated alpha-linolenic acid (CLNA) in a neonatal pig model. *Food Chem Toxicol* **2014**, 64, 119-25.
38. McFarlin, B. K.; Strohacker, K. A.; Kueht, M. L., Pomegranate seed oil consumption during a period of high-fat feeding reduces weight gain and reduces type 2 diabetes risk in CD-1 mice. *Brit J Nutr* **2008**, 102 (1), 54-59.
39. Chen, P.-H.; Chen, G.-C.; Yang, M.-F.; Hsieh, C.-H.; Chuang, S.-H.; Yang, H.-L.; Kuo, Y.-H.; Chyuan, J.-H.; Chao, P.-M., Bitter melon seed oil–attenuated body fat accumulation in diet-induced obese mice is associated with cAMP-dependent protein kinase activation and cell death in white adipose tissue. *The Journal of nutrition* **2012**, 142 (7), 1197-1204.
40. Vroegrijk, I. O.; van Diepen, J. A.; van den Berg, S.; Westbroek, I.; Keizer, H.; Gambelli, L.; Hontecillas, R.; Bassaganya-Riera, J.; Zondag, G. C.; Romijn, J. A., Pomegranate seed oil, a rich source of punicic acid, prevents diet-induced obesity and insulin resistance in mice. *Food Chem Toxicol* **2011**, 49 (6), 1426-1430.
41. Kohno, H.; Suzuki, R.; Yasui, Y.; Hosokawa, M.; Miyashita, K.; Tanaka, T., Pomegranate seed oil rich in conjugated linolenic acid suppresses chemically induced colon carcinogenesis in rats. *Cancer Sci* **2004**, 95 (6), 481-486.
42. Yuan, G.; Chen, X.; Li, D., Modulation of peroxisome proliferator-activated receptor gamma (PPAR gamma) by conjugated fatty acid in obesity and inflammatory bowel disease. *J Agric Food Chem* **2015**, 63 (7), 1883-95.
43. Su, C. G.; Wen, X.; Bailey, S. T.; Wen, J.; Rangwala, S. M.; Keilbaugh, S. A.; Flanigan, A.; Murthy, S.; Lazar, M. A.; Wu, G. D., A novel therapy for colitis utilizing PPAR- γ ligands to inhibit the epithelial inflammatory response. *J Clin Invest* **1999**, 104 (4), 383.
44. Bassaganya-Riera, J.; DiGuardo, M.; Climent, M.; Vives, C.; Carbo, A.; Jouni, Z. E.; Einerhand, A. W.; O'Shea, M.; Hontecillas, R., Activation of PPARgamma and delta by dietary punicic acid ameliorates intestinal inflammation in mice. *Br J Nutr* **2011**, 106 (6), 878-86.
45. Lewis, S. N.; Brannan, L.; Guri, A. J.; Lu, P.; Hontecillas, R.; Bassaganya-Riera, J.; Bevan, D. R., Dietary α -Eleostearic Acid Ameliorates Experimental Inflammatory Bowel Disease in Mice by Activating Peroxisome Proliferator-Activated Receptor- γ . *Plos One* **2011**, 6.

46. Bassaganya-Riera, J.; Reynolds, K.; Martino-Catt, S.; Cui, Y.; Hennighausen, L.; Gonzalez, F.; Rohrer, J.; Benninghoff, A. U.; Hontecillas, R., Activation of PPAR γ and δ by conjugated linoleic acid mediates protection from experimental inflammatory bowel disease. *Gastroenterology* **2004**, *127* (3), 777-791.
47. Ewaschuk, J. B., Bioproduction of conjugated linoleic acid by probiotic bacteria occurs in vitro and in vivo in mice. *J Nutr* **2006**, *136*.
48. Bassaganya-Riera, J.; Viladomiu, M.; Pedragosa, M.; De Simone, C.; Carbo, A.; Shaykhtudinov, R.; Jobin, C.; Arthur, J. C.; Corl, B. A.; Vogel, H.; Storr, M.; Hontecillas, R., Probiotic bacteria produce conjugated linoleic acid locally in the gut that targets macrophage PPAR gamma to suppress colitis. *PLoS One* **2012**, *7* (2), e31238.
49. Weber, L.-M.; Fischer, A.; Scholz, S.; Metzke, D.; Baumgart, D. C., Impact of Proinflammatory Cytokines and Mesalamine on the Expression of the Tight Junction Protein Claudin-1 in Intestinal Epithelial Cells. *Gastroenterology* **2017**, *152* (5), S740.
50. Mankertz, J.; Schulzke, J.-D., Altered permeability in inflammatory bowel disease: pathophysiology and clinical implications. *Curr opin in gastroen* **2007**, *23* (4), 379-383.
51. Rana, A. S., Mechanism of cytokine modulation of epithelial tight junction barrier. *Frontiers in Bioscience* **2009**, Volume (14), 2765.
52. Goncalves, Pedro; Araújo, Joao; Ricardo, Di; Santo, James, A Cross-Talk Between Microbiota-Derived Short-Chain Fatty Acids and the Host Mucosal Immune System Regulates Intestinal Homeostasis and Inflammatory Bowel Disease *Inflamm Bowel Dis* **2018**.
53. Fujio-Vejar, S.; Vasquez, Y.; Morales, P.; Magne, F.; Vera-Wolf, P.; Ugalde, J. A.; Navarrete, P.; Gotteland, M., The Gut Microbiota of Healthy Chilean Subjects Reveals a High Abundance of the Phylum Verrucomicrobia. *Front Microbiol* **2017**, *8*, 1221.
54. Walujkar, S. A.; Dhotre, D. P.; Marathe, N. P.; Lawate, P. S.; Bharadwaj, R. S.; Shouche, Y. S., Characterization of bacterial community shift in human Ulcerative Colitis patients revealed by Illumina based 16S rRNA gene amplicon sequencing. *Gut Pathog* **2014**, *6* (1), 22.
55. Munyaka, P. M.; Rabbi, M. F.; Khafipour, E.; Ghia, J. E., Acute dextran sulfate sodium (DSS)-induced colitis promotes gut microbial dysbiosis in mice. *J Basic Microbiol* **2016**, *56* (9), 986-98.
56. Druart, C.; Dewulf, E. M.; Cani, P. D.; Neyrinck, A. M.; Thissen, J. P.; Delzenne, N. M., Gut microbial metabolites of polyunsaturated fatty acids correlate with specific fecal bacteria and serum markers of metabolic syndrome in obese women. *Lipids* **2014**, *49* (4), 397-402.
57. Kuwahara, T.; Yamashita, A.; Hirakawa, H.; Nakayama, H.; Toh, H.; Okada, N.; Kuhara, S.; Hattori, M.; Hayashi, T.; Ohnishi, Y., Genomic analysis of *Bacteroides fragilis* reveals extensive DNA inversions regulating cell surface adaptation. *Proceedings of the National Academy of Sciences of the United States of America* **101** (41), 14919-14924.

■ FIGURE CAPTIONS

Figure 1. Preparation and purity detection of CLNA1 and CLNA2.

(A) Separation of CLNA1 and CLNA2 by liquid chromatograph. (B) Mass spectrum of CLNA1 and CLNA2. (C) Chemical structures of conjugated linolenic acid (CLNA) isomers used in this study (CLNA1: c9, t11, c15-CLNA, CLNA2: t9, t11, c15-CLNA).

Figure 2. Symptoms of DSS-induced colitis.

(A) Body weight, (B) disease activity index (DAI), (C) colon length, (D) histological examination (the scale bars are 200 μ m). (E) colonic histological injury.

Data are presented as mean \pm SEM (n =8 mice per group). *: p < 0.05, **: p < 0.01 and ***: p < 0.001, ****: P < 0.0001 compared with DSS group.

Figure 3. Effects of CLNA on inflammatory cytokines in colonic tissues.

(A) IL-1 β , (B) TNF- α , (C) IL-10, (D) IL-6, and (E) PPAR γ .

Data are presented as mean \pm SEM (n =8 mice per group). *: p < 0.05, **: p < 0.01 and ***: p < 0.001, ****: p < 0.0001 compared with DSS group.

Figure 4. Effects of CLNA on the mucous layer.

(A) Alcian blue staining (scale bar = 200 μ m), (B) concentration of MUC2, (C) expression of ZO-1 in colon, (D) expression of Occludin in colon, (E) expression of E-cadherin1 in colon, (F) expression of Claudin-3 in colon.

Data are presented as mean \pm SEM (n =8 mice per group). *: p < 0.05, **: p < 0.01 and

686 ***: $p < 0.001$, ****: $P < 0.0001$ compared with DSS group.

687

688 **Figure 5. Effects of CLNA on the activity of oxidative-stress-related enzymes in**
689 **the colon.**

690 (A) CAT, (B) GSH, (C) SOD, and (D) MPO.

691 Data are presented as mean \pm SEM (n =8 mice per group). *: $p < 0.05$, **: $p < 0.01$ and

692 ***: $p < 0.001$, ****: $p < 0.0001$ compared with DSS group.

693

694 **Figure 6. Concentration of CLNA and CLA in the blood, liver and colonic content.**

695 (A) The composition of main fatty acids in blood. (B) The concentration of CLNA and

696 CLA in the colonic content. (C) The concentration of CLNA1 and CLNA2 in liver.

697 Data are presented as mean \pm SEM (n =8 mice per group). *: $p < 0.05$, **: $p < 0.01$ and

698 ***: $p < 0.001$, ****: $p < 0.0001$ compared with DSS group.

699

700 **Figure 7. Evaluation of Illumina MiSeq sequencing data showing that CLNA could**
701 **modulate the overall structure of gut microbiota.**

702 (A) Microbial distribution at the phylum level. (B) α -Diversity indicated by the Chao1

703 index and Shannon index. (C) Cladogram. (D) Distribution histogram based on LDA,

704 with a log LDA score above 3.0. (E) Correlation analysis of significant taxa, colitis

705 indexes, tight junction proteins, antioxidant enzymes, cytokines in the colon and the

706 concentration of colonic CLA. Only significant correlations (*: $p < 0.05$, **: $p < 0.01$)

707 are displayed.

■ TABLEs

Table 1. The composition of fatty acids of every group.

Group		Composition				
CLNA1	93.09% CLNA1	6.91% ALA				
CLNA2	94.09% CLNA2	5.91%CLNA1				
CLNA Mix	1.18% C18:0	3.49% C18:1	0.48% C18:2	13.23% ALA	72.65% CLNA1	8.97% CLNA2
PA Mix	76.46% PA	2.14% C9:4	3.71% C16:0	3.15% C18:0	5.94% C18:1	8.60% C18:2

Table 2. The component of standard laboratory chow.

Component	Content (g/kg)
Water	98.0
Crude ash	51.4
Crude protein	190.1
Crude fat	49.6
Crude fiber	25.7
Calcium	11.3
Phosphorus	7.0

Table 3. The standard for evaluation of the disease activity index.

Weight Loss (%)	Occult Blood or Gross Bleeding	Stool Consistency	Score
0	Negative	Normal	0
1-5	Negative	Loose Stool	1
6-10	Hemoccult Positive	Loose Stool	2
11-15	Hemoccult Positive	Diarrhea	3
>15	Gross Bleeding	Diarrhea	4

Normal stools = well formed pellets; loose stools = pasty stool that does not stick to the anus; and diarrhea = liquid stools that sticks to the anus




Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6





Figure 7



TOC GRAPHIC